deltatrials
Terminated PHASE2 INTERVENTIONAL 7-arm NCT04779151

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)

An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Biliary Tract Cancer Clear Cell Renal Cell Carcinoma Gastric Adenocarcinoma Gastro-oesophageal Adenocarcinoma Head and Neck Cancer Pancreatic Ductal Adenocarcinoma Platinum-sensitive Urothelial Bladder Cancer Urothelial Bladder Cancer
Interventions Dostarlimab Niraparib
Updated 7 times since 2021 Last updated: Nov 24, 2025 Started: Apr 7, 2021 Primary completion: Feb 25, 2025 Completion: Feb 25, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Abandon of the partner, GSK

Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris

See all terminations from Gustave Roussy, Cancer Campus, Grand Paris

Other Biliary Tract Cancer trials with similar outcome

Browse all Biliary Tract Cancer trials

A PHASE2 clinical study on Biliary Tract Cancer and Clear Cell Renal Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Gustave Roussy, Cancer Campus, Grand Paris and has accumulated 7 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2021 – ~Sep 2022 · 17 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Apr 2024 · 14 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshotSuspended~Jan 2026 – present · 8 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Sep 2024 — Jan 2026 [monthly]

    Suspended PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  5. Feb 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Apr 2021 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gustave Roussy, Cancer Campus, Grand Paris
Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations